reason report
surpris challeng writ larg guidanc market
bottom line yesterday report result beat
consensu estim revenu earn
also beat above-consensu forecast revenu
ep revenu upsid came better expect
perform mainli legaci product includ neulasta epogen
sensipar compani guidanc revenu declin
ep flat despit mid singl
digit share count declin larg share buy-back
compani fulli explain assumpt behind guidanc
price flat signific headwind larg legaci
product franchis outlook final reflect concern
anticip model sever year guidanc certainli
seem incorpor signific eros sensipar us
sale gener also appear assum substanti eros
neulasta us sale well model modest declin
revenu stabil top line year
given size compani revenu base revenu
optim profit op margin tax rate
hard see addit lever manag dispos
buyback compani pipelin lack major late
stage program particularli fulli own one could offer near term
revenu growth pivot trial excit cohort phase
earli phase ii program intrigu bispecif kra etc
unlik materi contributor growth
guarante off-set like continu eros
late cycl legaci product base quarter result
manag comment make moder chang
revenu forecast
ep estim
chang chang peer compani multipl lower price
target reiter market perform rate amgen
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million dilut non-gaap ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target inc stock rate market perform
one first gener pioneer biopharmaceut industri succeed
basi build three massiv revenu pillar legaci product era three
product franchis epo epogen aranesp gcsf neulasta enbrel
face array brand gener competitor mean associ
revenu total like steadili declin offset outlook
number recent develop acquir product growth profit potenti
view unlik match legaci brand least mani year amgen
manag respond challeng restructur compani expens base
initi dividend lever compani balanc sheet cash trap off-shore
gener make legaci product compar peer regard
defens stock also one lack explos upsid potenti typic associ
breakthrough rapidli grow biotherapeut stock
total revenu beat boost neulasta sensipar total revenu
consensu estim
product sale grew yoy grew compar result total product sale
beat consensu estim yoy volum growth
partial off-set price headwind revenu beat primarili contribut
neulasta sensipar part beat neulasta due one-tim
purchas us biomed advanc research develop author barda
neulasta recent revenu eros biosimilar competit shown appear
taken paus although revenu trajectori seem highli uncertain base
manag commentari formal guidanc launch second neulasta biosimilar
januari udenyca coheru potenti addit biosimilar launch later appear
contribut impli revenu eros guidanc sensipar contribut
anoth beat vs consensu vs thank delay expect
gener entri could still uncertain product sale drag
kyproli vs consensu vs aranesp vs consensu vs
us enbrel sale line consensu estim yoy
declin enbrel sale mainli driven volum declin lower net sell price
continu lose ground biosimilar yoy qoq declin
compani signal epo franchis also face increas biosimilar pressur
us next year compani expect overal net price portfolio see mid-singl
digit declin gener tougher price environ go forward
favor tax rate share repurchas propel ep growth gross margin
line consensu estim rel stabl compar
prior period expens grew yoy sequenti sg expens increas
year ago sequenti repres total product sale
compani comment increas consist typic underli spend pattern
overal oper margin contract last quarter
tax rate quarter non-gaap ep came repres
growth yoy repurchas share common stock total cost
quarter reduc dilut share count compar end
compani still remain stock repurchas author
manag rule anoth acceler share repurchas asr
guid declin revenu ep first time compani last
year far tell guid absolut revenu declin come
financi year compani suggest revenu full year
compar recent consensu estim upper bound
guidanc rang still full year revenu mid-point
guidanc repres yoy declin major reason lower guidanc wide
rang uncertainti time intens competit gener sensipar
biosimilar neulasta compani also guid tax rate rang
basi non- basi guidanc ep
guidanc non-gaap ep note upper
bound non-gaap ep guidanc fall consensu estim
mid-point guidanc lower non-gaap ep compani
expect capit expenditur year approxim lower
consensu estim guidanc may attempt
re-set forward analyst expect lower come amid slew cautiou guid across
industri see etc exactli anticip research
quarterli outlook pain growth adjust associ loss net posit price
larg compani
aimovig show strong launch trajectori despit free drug heavi discount sinc
launch last may first cgrp receptor antibodi migrain aimovig shown
strong trajectori prescript growth final trajectori start translat
meaning revenu us sale aimovig although benefit one
time adjust prior period allow announc seven month
us market patient aimovig line bullish thesi
class see note littl headach robust aimovig trend point
blockbust class compani disclos proport paid prescript aimovig
increas recent launch dtc campaign
manag seen promis earli result howev anoth two compet
product alreadi launch start captur payer contract still lot
work ensur insur coverag aimovig realiz full potenti asset
lower price repatha result signific volum inflect sinc recent launch
lower price list price version repatha option captur volum
due time launch compani expect major payer
cover new version far medicar live gain access
low list price option reduc out-of-pocket cost proport convert lower price
version like increas materi pose signific headwind report
revenu growth product least near term
continu enthusiasm kra earli stage program first readout
clinic trial inhibitor mutat kra occur
lung adenocarcinoma wide rang solid tumor includ
pancreat cancer colorect cancer current phase clinic trial patient
solid tumor kra mutat rapidli progress dose
escal portion trial investor express interest platform kra
consid undrugg target decad manag comment
seen interest earli hint clinic activ look forward share data sometim
year inhibitor phase clinic trial acut
myeloid leukemia aml multipl myeloma mm broad rang relapsed/refractori
hematolog malign pro-surviv protein implic apoptosi one
protein frequent up-regul number cancer type preclin data
promis shown efficaci treat mous model aml mm
data suggest could addit synergist activ inhibitor
venclexta manag mention plan combin studi
inhibitor initi phase clinic data singl agent expect well
pipelin laden earli stage molecul meaning catalyst
built broad portfolio bispecif antibodi target hematolog malign solid tumor
molecul still preclin earli stage clinic develop investor
start get interest potenti promis earli result bcma
bite bite compani expect present updat result
year well initi data half-lif extend bcma bite
egfrviii bite although molecul still mani year commerci
launch compani get credit show earli proof-of-concept last
year data first announc
moder model updat above-consensu forecast pt lower base
quarter result manag comment increas revenu forecast slightli
reduc forecast follow year revenu forecast
remain recent consensu forecast oper expens
also lower reflect manag guidanc ep estim higher
lower ep forecast line consensu
chang chang peer compani multipl price target
lower reiter market perform rate
price target inc base averag three approach
believ reason basi valu stock today approach simpl price
earn multipl larg cap us eu larg cap biopharma stock sni
rhhbi gsk nv price sale multipl larg cap biotechnolog pharma
compani novo nv discount cash flow dcf use
rel multipl larg cap biopharma compani ep appli
ep estim give one year futur valu use
establish larg cap futur revenu multipl sale appli
revenu forecast give futur valu final dcf
valuat base current outlook compani exist product probability-
weight revenu contribut late stage pipelin program discount
compani wacc give fair valu today averag three
approach give price target
risk view outlook valuat includ major chang label
price reimburs coverag compani legaci product failur
compani growth portfolio achiev futur sale forecast risk includ develop
delay disappoint earlier stage pipelin asset earlier signific eros
compani legaci product biosimilar innov competit shortfal
compani effort improv oper margin would also materi affect outlook
valuat would larg dilut acquisit therapeut area platform
sale
interest expens incom net
non-gaap incom tax
share count period basic
share count period dilut
guidanc
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
brand
type event
event trial detail
date known
up/down
leerink view
phase candor trial combin
darzalex dexamethason
svb leerink llc research compani file
million
corp partner revenue incl royalti
po probabl success fda approv
sbv leerink llc research compani file
million
sale
total expens exclud revenue sharing/incl sg
 total revenu
sg total revenu excl profit share
profit share total revenu
sbv leerink llc research compani file
analysi stock price svb leerink target
method model larg cap healthcar growth stock ep multipl
ep appli amgen ep
svb leerink updat ep estim
current averag ep multipl consensu ep
compar slow grow us eu larg cap biopharma
impli target price ep
revenu multipl appli svb leerink revenu forecast
svb leerink updat revenu estim
current averag larg cap biopharma multipl revenu
impli valu fy revenu
impli target price ep use us pharma compar
method dcf adjust debt declin flow
stabl termin cash flow growth discount
present valu flow termin valu
averag method
svb leerink llc research compani file factset
